Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease
The recent development of tau-specific positron emission tomography (PET) tracers enables in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease (AD). Tau PET imaging may become a useful biomarker for clinical diagnosis and tracking of disease progressio...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-08-01
|
| Series: | NeuroImage |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1053811917304585 |
| _version_ | 1829484795707523072 |
|---|---|
| author | Anne Maass Susan Landau Suzanne L. Baker Andy Horng Samuel N. Lockhart Renaud La Joie Gil D. Rabinovici William J. Jagust |
| author_facet | Anne Maass Susan Landau Suzanne L. Baker Andy Horng Samuel N. Lockhart Renaud La Joie Gil D. Rabinovici William J. Jagust |
| author_sort | Anne Maass |
| collection | DOAJ |
| description | The recent development of tau-specific positron emission tomography (PET) tracers enables in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease (AD). Tau PET imaging may become a useful biomarker for clinical diagnosis and tracking of disease progression but there is no consensus yet on how tau PET signal is best quantified. The goal of the current study was to evaluate multiple whole-brain and region-specific approaches to detect clinically relevant tau PET signal. Two independent cohorts of cognitively normal adults and amyloid-positive (Aβ+) patients with mild cognitive impairment (MCI) or AD-dementia underwent [18F]AV-1451 PET. Methods for tau tracer quantification included: (i) in vivo Braak staging, (ii) regional uptake in Braak composite regions, (iii) several whole-brain measures of tracer uptake, (iv) regional uptake in AD-vulnerable voxels, and (v) uptake in a priori defined regions. Receiver operating curves characterized accuracy in distinguishing Aβ- controls from AD/MCI patients and yielded tau positivity cutoffs. Clinical relevance of tau PET measures was assessed by regressions against cognition and MR imaging measures. Key tracer uptake patterns were identified by a factor analysis and voxel-wise contrasts. Braak staging, global and region-specific tau measures yielded similar diagnostic accuracies, which differed between cohorts. While all tau measures were related to amyloid and global cognition, memory and hippocampal/entorhinal volume/thickness were associated with regional tracer retention in the medial temporal lobe. Key regions of tau accumulation included medial temporal and inferior/middle temporal regions, retrosplenial cortex, and banks of the superior temporal sulcus. Our data indicate that whole-brain tau PET measures might be adequate biomarkers to detect AD-related tau pathology. However, regional measures covering AD-vulnerable regions may increase sensitivity to early tau PET signal, atrophy and memory decline. |
| first_indexed | 2024-12-14T22:34:15Z |
| format | Article |
| id | doaj.art-c8f2f0e4fba14d088d776fe3fa45666f |
| institution | Directory Open Access Journal |
| issn | 1095-9572 |
| language | English |
| last_indexed | 2024-12-14T22:34:15Z |
| publishDate | 2017-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | NeuroImage |
| spelling | doaj.art-c8f2f0e4fba14d088d776fe3fa45666f2022-12-21T22:45:12ZengElsevierNeuroImage1095-95722017-08-01157448463Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's diseaseAnne Maass0Susan Landau1Suzanne L. Baker2Andy Horng3Samuel N. Lockhart4Renaud La Joie5Gil D. Rabinovici6William J. Jagust7Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, United States; German Center for Neurodegenerative Diseases, Magdeburg, Germany; Correspondence to: Jagust Laboratory, Helen Wills Neuroscience Institute, 132 Barker Hall, MC #3190, University of California, Berkeley, CA 94720-3190, USA.Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, United StatesMolecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Lab, Berkeley, CA, United StatesHelen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, United StatesHelen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, United StatesMemory and Aging Center, University of California San Francisco, San Francisco, CA, United StatesHelen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, United States; Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Lab, Berkeley, CA, United States; Memory and Aging Center, University of California San Francisco, San Francisco, CA, United StatesHelen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, United States; Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Lab, Berkeley, CA, United States; Memory and Aging Center, University of California San Francisco, San Francisco, CA, United StatesThe recent development of tau-specific positron emission tomography (PET) tracers enables in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease (AD). Tau PET imaging may become a useful biomarker for clinical diagnosis and tracking of disease progression but there is no consensus yet on how tau PET signal is best quantified. The goal of the current study was to evaluate multiple whole-brain and region-specific approaches to detect clinically relevant tau PET signal. Two independent cohorts of cognitively normal adults and amyloid-positive (Aβ+) patients with mild cognitive impairment (MCI) or AD-dementia underwent [18F]AV-1451 PET. Methods for tau tracer quantification included: (i) in vivo Braak staging, (ii) regional uptake in Braak composite regions, (iii) several whole-brain measures of tracer uptake, (iv) regional uptake in AD-vulnerable voxels, and (v) uptake in a priori defined regions. Receiver operating curves characterized accuracy in distinguishing Aβ- controls from AD/MCI patients and yielded tau positivity cutoffs. Clinical relevance of tau PET measures was assessed by regressions against cognition and MR imaging measures. Key tracer uptake patterns were identified by a factor analysis and voxel-wise contrasts. Braak staging, global and region-specific tau measures yielded similar diagnostic accuracies, which differed between cohorts. While all tau measures were related to amyloid and global cognition, memory and hippocampal/entorhinal volume/thickness were associated with regional tracer retention in the medial temporal lobe. Key regions of tau accumulation included medial temporal and inferior/middle temporal regions, retrosplenial cortex, and banks of the superior temporal sulcus. Our data indicate that whole-brain tau PET measures might be adequate biomarkers to detect AD-related tau pathology. However, regional measures covering AD-vulnerable regions may increase sensitivity to early tau PET signal, atrophy and memory decline.http://www.sciencedirect.com/science/article/pii/S1053811917304585Tauβ-amyloidPositron emission tomographyAV-1451BiomarkerAlzheimer's disease |
| spellingShingle | Anne Maass Susan Landau Suzanne L. Baker Andy Horng Samuel N. Lockhart Renaud La Joie Gil D. Rabinovici William J. Jagust Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease NeuroImage Tau β-amyloid Positron emission tomography AV-1451 Biomarker Alzheimer's disease |
| title | Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease |
| title_full | Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease |
| title_fullStr | Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease |
| title_full_unstemmed | Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease |
| title_short | Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease |
| title_sort | comparison of multiple tau pet measures as biomarkers in aging and alzheimer s disease |
| topic | Tau β-amyloid Positron emission tomography AV-1451 Biomarker Alzheimer's disease |
| url | http://www.sciencedirect.com/science/article/pii/S1053811917304585 |
| work_keys_str_mv | AT annemaass comparisonofmultipletaupetmeasuresasbiomarkersinagingandalzheimersdisease AT susanlandau comparisonofmultipletaupetmeasuresasbiomarkersinagingandalzheimersdisease AT suzannelbaker comparisonofmultipletaupetmeasuresasbiomarkersinagingandalzheimersdisease AT andyhorng comparisonofmultipletaupetmeasuresasbiomarkersinagingandalzheimersdisease AT samuelnlockhart comparisonofmultipletaupetmeasuresasbiomarkersinagingandalzheimersdisease AT renaudlajoie comparisonofmultipletaupetmeasuresasbiomarkersinagingandalzheimersdisease AT gildrabinovici comparisonofmultipletaupetmeasuresasbiomarkersinagingandalzheimersdisease AT williamjjagust comparisonofmultipletaupetmeasuresasbiomarkersinagingandalzheimersdisease |